News & articles

April 11, 2018Chicago, IL and Australia The MPN (Myeloproliferative Neoplasms) Research Foundation (MPNRF) and MPN Alliance Australia (MPN AA) are proud to announce a research partnership focused on the MPN Interferon Initiative. MPNRF and MPN AA are both patient advocacy organizations who work on behalf of patients with myeloproliferative neoplasms, a group of rare, chronic… Read More »MPN ALLIANCE AUSTRALIA AND MPN RESEARCH FOUNDATION PARTNER TO SUPPORT RESEARCH

MPN Research Foundation is excited to have sponsored the creation of the NCCN (National Cancer Center Network) MPN patient guidelines. To follow up on this publication, which helps inform patients about best-practices in care for MPNs, the NCCN is hosting a free live webinar focusing on myeloproliferative neoplasms (MPN) especially for patients and their family… Read More »NCCN TO HOST WEBINAR FOR MPN PATIENT GUIDELINES

On March 31st, 2018 roughly 100 hematologists/oncologists and MPN experts from Asia, as well as Europe and the United States, came together at the 3rd annual MPN Asia event to present and discuss recent updates and scientific advancements of Myeloproliferative Neoplasms. A few key takeaways from the event came from the Ropeginterferon vs Hydroxyurea trial. This… Read More »After a 2-year study, ropeginterferon proves more effective than hydroxyurea

Your copy of the Spring 2019 Newsletter from the MPN Research Foundation is now available. You can click here to read it but if you would like a printed copy, please let us know by emailing Lexi Moore at lmoore@mpnrf.org. Filled with the latest news from the global MPN community, the newsletter includes information about MPNRF’s exciting 2019… Read More »MPNRF’S SPRING 2019 NEWSLETTER HAS ARRIVED!

After completing a number of clinical trials, The MPN community was disappointed when a promising compound in development for myelofibrosis, momelotinib, was discontinued by Gilead Sciences Inc. So, it was a great relief when, in 2018, Sierra Oncology acquired momelotinib with the intention of continuing the development of the drug.  Sierra Oncology is planning a… Read More »UPDATE ON PROMISING MF TREATMENT, MOMELOTINIB

A TGF-Beta inhibitor – AVID 200 – is joining the race for new therapies for myeloproliferative neoplasms. In a press release published today, Forbius Biologics Inc. announced that the first myelofibrosis patient has been dosed in their phase 1b myelofibrosis trial of AVID 200, a novel TGF-Beta inhibitor. The investigator-initiated trial is being run by… Read More »CLINICAL TRIAL FOR AVID200 DOSES FIRST MF PATIENT

The MPN Research Foundation is celebrating our first annual Founder’s Day in memory of Robert (Bob) Rosen, the person who started it all almost 20 years ago. Today, May 6th is particularly special as it was Bob’s birthday, and we look forward to celebrating his legacy on this day for years to come. Bob was… Read More »MPNRF celebrates 1st annual Founder’s Day

Researchers in The Tisch Cancer Institute’s Myeloproliferative Neoplasms (MPN) Program at Mount Sinai is investing a novel class of drugs for MPN patients. “Our hope is that idasanutlin will improve long-term survival in patients with chronic blood cancers,” says Dr. Hoffman, MD, at the Icahn School of Medicine at Mount Sinai. He says the mission… Read More »RESEARCHERS AT MOUNT SINAI INVESTIGATE A NOVEL CLASS OF DRUGS FOR MPN PATIENTS

Today the American Society of Clinical Oncology is wrapping up their 2019 ASCO meeting held annually in Chicago, IL. Although ASCO does not focus solely on blood cancers, the MPN Research Foundation looks forward to attending each year to discuss the status of MPN research and treatments with oncology professionals, drug companies, and fellow advocacy groups.… Read More »MPN UPDATES FROM ASCO 2019

Sierra Oncology announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to momelotinib, a JAK1, JAK2, and ACVR1 inhibitor, for the treatment of patients with intermediate/high-risk myelofibrosis. “Fast Track designation for momelotinib highlights the serious and significant unmet needs of patients with myelofibrosis who have previously received a JAK inhibitor.… Read More »POSSIBLE NEW MYELOFIBROSIS DRUG GETS FAST TRACKED BY THE FDA